Cover Image


Diabetes -- KOL Insight and Consensus Outlook Modules

出版商 FirstWord 商品編碼 284609
出版日期 內容資訊 英文 224 Pages
商品交期: 最快1-2個工作天內
Back to Top
糖尿病:KOL的洞察及達成共識的展望 Diabetes -- KOL Insight and Consensus Outlook Modules
出版日期: 2014年02月27日 內容資訊: 英文 224 Pages

肥胖層級及糖尿病的罹患率,在先進、新興市場都上升,5年的年複合成長率為12%以上,2012年的市值達到319億美元。預計至2030年糖尿病的患者數約為2倍達3億4,700萬人成為(90%為第二型糖尿病患者)。糖尿病市場5年以年複合成長率11%成長,預計達540億美元規模。該市場的主要4家公司為Novo Nordisk、Sanofi、Eli Lilly 及 Merck。

本報告提供糖尿病市場概括檢討,和美國、歐洲屈指可數的KOL獨家專訪提供的KOL洞察(KOL Insight)模組,及提供產品層級銷售資料的年度實際成果與預測的資料分析模組,為您概述為以下內容。


  • KOL洞察報告
    • 全球糖尿病市場上現在及預測的治療趨勢、臨床產品,及商業性變化的定性分析的提供:來自第一流臨床醫生的詳細專門見解
    • 糖尿病市場趨勢背景中的市場主要企業、產品、後期開發階段的平台治療藥、產品定位比較
  • 活動公告
    • 促進糖尿病治療趨勢變化的重要活動相關的最新KOL見解


  • 共識報告
    • 一流分析師、中介企業所選的主要糖尿病市場預測的參數中預測的定性數量變化相關詳細的5年共識展望
    • 糖尿病市場規模、產品銷售額、各企業的市場佔有率、競爭情形及詳細市場預測的圖表
  • 互動Excel文件
    • 為了深入主要趨勢、評估的詳細市場、產品銷售資料


  • 內容
  • FirstWord 分析焦點
  • 調查手法
  • 糖尿病市場
  • 主要的糖尿病治療藥開發者
  • 糖尿病的各級趨勢
  • Lantus (Insulin glargine; Sanofi) 預測
  • Levemir (Insulin Detemir; Novo Nordisk) 預測
  • Tresiba (Insulin Degludec; Novo Nordisk) 預測
  • Ryzodeg (degludecPlus; Novo Nordisk) 預測
  • NovoRapid/NovoLog (insulin aspart; Novo Nordisk) 預測
  • Humalog (insulin lispro; Eli Lilly) 預測
  • Apidra (insulin glulisine; Sanofi) 預測.
  • NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) 預測
  • Januvia franchise (sitagliptin; Merck & Co) 預測
  • Galvus franchise (vildagliptin; Novartis) 預測
  • Onglyza franchise (vildagliptin; Bristol-Myers Squibb/AstraZeneca/ 大塚製藥) 預測
  • Nesina franchise (alogliptin; 武田藥品工業) 預測
  • Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) 預測
  • Byetta (Exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) 預測
  • Bydureon (Exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) 預測
  • Victoza (liraglutide; Novo Nordisk) 預測
  • Lyxumia (lixisenatide; Sanofi) 預測.
  • Invokana (canagliflozin; Johnson & Johnson/田邊三菱製藥) 預測
  • Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) 預測
  • Actos (PIOGLITAZONE; 武田藥品工業) 預測
  • U300 (Insulin glargine; Sanofi) 預測
  • LY2605541 (insulin peglispro; Eli Lilly) 預測
  • LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) 預測
  • IDeglira (liraglutide + insulin degludec; Novo Nordisk) 預測
  • Afrezza (Technosphere Insulin; MannKind Corporation) 預測
  • FIAsp (insulin aspart; Novo Nordisk) 預測
  • Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) 預測
  • LY2189265 (dulaglutide; Eli Lilly) 預測
  • BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) 預測



The medium term: battle lines are drawn

The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both established and emerging markets have seen the sector return a 5 year compound annual growth rate (CAGR) of over 12% to reach US$31.9 billion in 2012. It is estimated that 347 million people have the disease - 90% of whom are Type II diabetes sufferers - and this figure could almost double by 2030.

The big four companies in diabetes - Novo Nordisk, Sanofi, Eli Lilly and Merck - are locked in a battle for supremacy which is set to continue over the medium term. While Novo Nordisk currently leads the pack, Sanofi is close behind. With Novo Nordisk's approval of Tresiba (insulin degedec) stalled in the US over safety concerns, Sanofi latest version of Lantus U300 (insulin glargine) could capitalise. Bristol Myers-Squibb and AstraZeneca are just two of the other players set to increase their sales significantly in this busy marketplace by 2017.

The diabetes market will continue on an upward trajectory, and an estimated 5 year CAGR of 11% will see the sector top US$54 billion - the question is which companies will have a slice to this market, and how big will it be?

What's in the pipeline?

Finding market voice for new products in diabetes depends critically on price and differentiation. Cost of treatment is already an issue and resistance can be expected from health payers if new products offer only marginal therapeutic or patient management benefits. For example, excitement about Sanofi's U300 (insulin glargine) is because it shows differentiation to Lantus with "peakless" delivery and longer duration. Eli Lilly's weekly dose dulaglutide may offer advantages over other launched and pipeline GLP-1 products such as such as GSK's Eperzan (albiglutide) and BMS/AZ/Amylin's Bydureon (exanatide) but meaningful advantages need to be shown for success in the market.

What the Future Holds: is there a Game Changer on the Horizon?

Don't expect a revolution in diabetes treatment soon. New products coming to market are essentially incremental improvements over current approaches, with better safety profiles and geared to improving patient compliance.

The real prize will be for the company that can bring a paradigm shift to the treatment of diabetes. Upsetting the status quo will require a fundamentally different approach - and some of these developments threaten the diabetes drugs manufacturers existing revenues.

Among the developments to be aware of are the threat of biosimilars, the development of an artificial pancreas 'closed loop' system, the wide implementation of which would be a doomsday development for drugs companies, and a DNA reverse vaccine for which early clinical results have shown promise.

A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers

For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative diabetes market forecast look no further than FirstWord's Therapy Trends: Diabetes. This comprehensive FirstWord research is available in two comprehensive modules:

  • The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe
  • The Consensus Outlook: Diabetes data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts' projections

KOL Insight

KOL Insight Report

  • A 220-page qualitative analysis of the current and predicted treatment trends, clinical products and commercial changes in the global diabetes market informed by in-depth expert views of leading clinicians
  • Compare the market's key players, products, late-stage pipeline drugs, product positioning, in the context of Diabetes market trends

Event Bulletins

  • Benefit from the latest KOL views about significant event driven changes in diabetes treatment trends

Consensus Outlook

Consensus Report

  • An in-depth 5-year Consensus Outlook report of predicted quantitative changes in key Diabetes market forecast parameters drawn from 13 leading analyst and brokerage companies
  • Chart diabetes market size, product sales, market share by company, competitive status and detailed market forecasts

Interactive Analytics File

  • Use the interactive Excel market analytics module of detailed market and product sales data from 2007 to 2017 to drill down and assess key trends.

Table of Contents

  • Contents
  • FirstWord Analysis Highlights.
  • Research Methodology
  • Diabetes Marketplace
  • Key Diabetes Developers
  • Diabetes Class Dynamics
  • Lantus (insulin glargine; Sanofi) forecast
  • Levemir (insulin detemir; Novo Nordisk) forecast.
  • Tresiba (insulin degludec; Novo Nordisk) forecast
  • Ryzodeg (degludecPlus; Novo Nordisk) forecast
  • NovoRapid/NovoLog (insulin aspart; Novo Nordisk) forecast
  • Humalog (insulin lispro; Eli Lilly) forecast
  • Apidra (insulin glulisine; Sanofi) forecast.
  • NovoMix/NovoLog Mix (insulin aspart + insulin aspart protamine; Novo Nordisk) forecast
  • Januvia franchise (sitagliptin; Merck & Co) forecast
  • Galvus franchise (vildagliptin; Novartis) forecast
  • Onglyza franchise (saxagliptin; Bristol-Myers Squibb/AstraZeneca/ Otsuka) forecast
  • Nesina franchise (alogliptin; Takeda) forecast
  • Tradjenta franchise (linagliptin; Boehringer Ingelheim/Eli Lilly) forecast
  • Byetta (exenatide; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast
  • Bydureon (exenatide once-weekly; Bristol-Myers Squibb/AstraZeneca/ Amylin) forecast
  • Victoza (liraglutide; Novo Nordisk) forecast
  • Lyxumia (lixisenatide; Sanofi) forecast.
  • Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe) forecast
  • Forxiga (dapagliflozin; Bristol-Myers Squibb/AstraZeneca) forecast
  • Actos (pioglitazone; Takeda) forecast
  • U300 (insulin glargine; Sanofi) forecast
  • LY2605541 (insulin peglispro; Eli Lilly) forecast
  • LY2963016 (biosimilar insulin glargine; Eli Lilly/Boehringer Ingelheim) forecast
  • IDeglira (liraglutide + insulin degludec; Novo Nordisk) forecast
  • Afrezza (Technosphere Insulin; MannKind Corporation) forecast
  • FIAsp (insulin aspart; Novo Nordisk) forecast.
  • Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast
  • LY2189265 (dulaglutide; Eli Lilly) forecast
  • BI-10773 (empagliflozin; Boehringer Ingelheim/Eli Lilly) forecast
Back to Top